(HealthDay)—There is no evidence that patients with diabetes who initiate insulin glargine have a higher risk of cancer than similar patients initiating human neutral protamine Hagedorn (NPH) insulin, according to a study ...
Aug 6, 2013
0
0
Insulin degludec (Tresiba), a new ultra-long-acting insulin, has a similar or reduced risk of recurrent hypoglycemia— low blood sugar— compared with the commercially available insulin glargine, a new meta-analysis study ...
Jun 18, 2013
0
0
(HealthDay)—For patients with type 1 diabetes, the novel, long-acting basal insulin LY2605541 yields greater improvement in glycemic control compared with insulin glargine, according to a study published online Nov. 27 ...
Jan 13, 2013
0
0
(HealthDay)—For patients with type 2 diabetes, following administration of a subcutaneous injection of a therapeutic dose of insulin glargine, glargine is minimally detectable in blood, and most of the plasma insulin concentration ...
Oct 25, 2012
0
0
A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared ...
Aug 27, 2012
0
0
Researchers at McMaster University have discovered that long-term insulin use does not harm people with diabetes or pre-diabetes or put them at risk of heart attacks, strokes or cancer.
Jun 11, 2012
0
0
